Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dicerna Pharmaceuticals, Inc. Announces FDA Clearance of Investigational New Drug Application for DCR-AUD, for the Treatment of Alcohol Use Disorder

07/29/2021 | 07:30am EDT

Dicerna Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration clearance of its Investigational New Drug (IND) application for DCR-AUD, the Company’s investigational RNAi candidate for the treatment of alcohol use disorder (AUD). AUD is a medical condition characterized by the inability to stop or control alcohol use despite social, occupational or health consequences. Aldehyde dehydrogenase, or ALDH2, is an enzyme that plays a key role in metabolizing alcohol. DCR-AUD has been shown to induce long-lasting liver-specific ALDH2 messenger RNA (mRNA) knockdown in nonclinical studies. By silencing ALDH2 in the liver and interrupting the alcohol metabolic pathway, DCR-AUD has the potential to induce real-time physiological feedback to help individuals seeking treatment for AUD regain control over harmful levels of alcohol use.


© S&P Capital IQ 2021
All news about DICERNA PHARMACEUTICALS, INC.
09/22DICERNA PHARMACEUTICALS : Names Rob Ciappenelli Chief Strategy Officer
MT
09/22DICERNA PHARMACEUTICALS : Announces New Executive Leadership Appointments
BU
09/22Dicerna Pharmaceuticals, Inc. Announces Executive Appointments
CI
09/21INSIDER SELL : Dicerna Pharmaceuticals
MT
09/07DICERNA PHARMACEUTICALS : Corporate Overview
PU
09/02DICERNA PHARMACEUTICALS : to Participate in 16th Annual Citi Biopharma Conference
BU
08/12DICERNA PHARMACEUTICALS : Corporate Overview
PU
08/12NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/11DICERNA PHARMACEUTICALS : B. Riley Lowers Dicerna Pharmaceuticals' PT to $35 from $49 on H..
MT
08/11DICERNA PHARMACEUTICALS : Goldman Sachs Cuts Dicerna Pharmaceuticals to Neutral From Buy, ..
MT
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 179 M - -
Net income 2021 -144 M - -
Net cash 2021 501 M - -
P/E ratio 2021 -11,4x
Yield 2021 -
Capitalization 1 656 M 1 656 M -
EV / Sales 2021 6,47x
EV / Sales 2022 6,51x
Nbr of Employees 302
Free-Float 91,8%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 21,30 $
Average target price 30,89 $
Spread / Average Target 45,0%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagán Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.-3.31%1 656
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.34.39%59 817
VERTEX PHARMACEUTICALS-22.31%47 634